Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Overview
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Companies Involved in Therapeutics Development
Boehringer Ingelheim Intertiol GmbH
Bristol-Myers Squibb Co
MorphoSys AG
Ningbo Wenda Pharmaceutical Technology Co Ltd
VYNE Therapeutics Inc
Zenith Epigenetics Ltd
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Drug Profiles
BI-894999 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CC-95775 - Drug Profile
Product Description
Mechanism Of Action
History of Events
NHWD-870 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pelabresib - Drug Profile
Product Description
Mechanism Of Action
History of Events
VYN-201 - Drug Profile
Product Description
Mechanism Of Action
History of Events
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Dormant Products
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Discontinued Products
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Product Development Milestones
Featured News & Press Releases
May 11, 2022: Zenith commences Phase IIb breast cancer combition therapy trial
Mar 30, 2022: VYNE Reports positive preclinical data for intra-articular injection of pan-BET inhibitor, VYN201, in an in vivo model of rheumatoid arthritis
Mar 07, 2022: VYNE reports positive preclinical data for lead BET Inhibitor, VYN201, in human skin model of vitiligo
Feb 22, 2022: Zenith Epigenetics announces dosing of first cancer patient with a combition of ZEN-3694 + Bristol Myers Squibb’s immune checkpoint inhibitor OPDIVO
Dec 12, 2021: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Nov 04, 2021: MorphoSys to present MANIFEST data from expanded hematology-oncology portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
Nov 04, 2021: Lead BET inhibitor, VYN201, demonstrates improvement in reducing fibrotic tissue mass and overall skin repair outcomes in preclinical study
Oct 26, 2021: Lead BET inhibitor, VYN201, significantly reduces expression of several key pro-inflammatory cytokines in preclinical studies
Sep 21, 2021: Zenith Epigenetics and Newsoara announce initiation of a randomized phase 2b metastatic castration-resistant prostate cancer (mCRPC) study
Aug 17, 2021: Zenith Epigenetics announces a publication in the jourl of Cancer Gene Therapy with compelling data for the treatment of ER-positive breast cancer patients
Jun 24, 2021: Zenith Epigenetics announces a publication highlighting the role of ZEN-3694 in overcoming resistance to therapies in metastatic castration-resistant prostate cancer
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the ongoing MANIFEST study of Pelabresib
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the Ongoing MANIFEST study of Pelabresib
Mar 15, 2021: Zenith Epigenetics announces dosing of first mCRPC patient with a combition of ZEN-3694 + Merck’s immune check point inhibitor KEYTRUDA
Jan 07, 2021: Constellation Pharmaceuticals appoints Brendan Delaney as Chief Commercial Officer
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Stage and Molecule Type, 2022

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indications, 2022
Number of Products under Development by Indications, 2022 (Contd..1)
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by Boehringer Ingelheim International GmbH, 2022
Pipeline by Bristol-Myers Squibb Co, 2022
Pipeline by MorphoSys AG, 2022
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2022
Pipeline by VYNE Therapeutics Inc, 2022
Pipeline by Zenith Epigenetics Ltd, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022